Mitochondrial peptide prevents Type-1 diabetes in mice, study finds

August 16, 2021
A new study of human cells in culture and live mice – by a research team at the University of Southern California (USC) – has shown that injections of an immune cell-regulating peptide can prevent the destruction of insulin-producing pancreatic cells that cause type-1 diabetes. It is very likely that the peptide could later be adapted for treatments for other autoimmune disorders as well. Type-1 diabetes or juvenile diabetes is characterised by the routine self-destruction of hormone-producing cells in specific regions of the pancreas. When immune cells mistakenly destroy healthy pancreatic cells that produce the sugar-regulating hormone insulin, the body will eventually lose the ability to control its blood sugar levels. USC researchers, however, have seen how treatment with a mitochondrial peptide known as MOTS-c prevents the onset of disease. Simply put, MOTS-c supports regulatory T cells, which are crucial to distinguishing between the body’s own cells and foreign pathogens; this reduces the amount of “killer” T cells that are activated to attack the insulin-producing cells. Mice that had been genetically engineered to develop type-1 diabetes were observed to have reduced activation of killer T cells following injections of MOTS-c; a subsequent study of human cells from both diabetic and non-diabetic patients also revealed that MOTS-c treatment reduced the activation of killer T cells. The study of human cells additionally revealed how type-1 diabetes patients have significantly lower levels of MOTS-c circulating in their blood compared to non-diabetic patients, further supplementing the researchers’ hypothesis. Unlike most other proteins which are encoded in the DNA in the nucleus, MOTS-c is encoded in the DNA of mitochondria, the “powerhouses” of cells that convert food to energy. MOTS-c was first thought to play a role only in counteracting diet-induced and age-dependent insulin resistance – effects commonly associated with exercising. “It’s been thought for the longest time that the immune system is exclusively encoded in the nuclear genome,” said USC Associate Professor of Gerontology Changhan David Lee. “Now we’re bringing into play an immune regulator that’s encoded in the mitochondrial genome.” According to Lee, the mitochondrial genome “encodes for previously unknown genes that yield small proteins with multiple physiological roles, including aging, exercise, metabolism, and immunity.” Further studies on the molecular mechanism of mitochondrial-encoded peptides such as MOTS-c may provide “novel therapeutic targets” for various autoimmune conditions.

A new study of human cells in culture and live mice – by a research team at the University of Southern California (USC) – has shown that injections of an immune cell-regulating peptide can prevent the destruction of insulin-producing pancreatic cells that cause type-1 diabetes. It is very likely that the peptide could later be adapted for treatments for other autoimmune disorders as well.

Type-1 diabetes or juvenile diabetes is characterised by the routine self-destruction of hormone-producing cells in specific regions of the pancreas. When immune cells mistakenly destroy healthy pancreatic cells that produce the sugar-regulating hormone insulin, the body will eventually lose the ability to control its blood sugar levels.

Read also: Diabetics could one day use remote-activated insulin-releasing device instead of needles

USC researchers, however, have seen how treatment with a mitochondrial peptide known as MOTS-c prevents the onset of disease. Simply put, MOTS-c supports regulatory T cells, which are crucial to distinguishing between the body’s own cells and foreign pathogens; this reduces the amount of “killer” T cells that are activated to attack the insulin-producing cells.

Mice that had been genetically engineered to develop type-1 diabetes were observed to have reduced activation of killer T cells following injections of MOTS-c; a subsequent study of human cells from both diabetic and non-diabetic patients also revealed that MOTS-c treatment reduced the activation of killer T cells.

The study of human cells additionally revealed how type-1 diabetes patients have significantly lower levels of MOTS-c circulating in their blood compared to non-diabetic patients, further supplementing the researchers’ hypothesis.

Unlike most other proteins which are encoded in the DNA in the nucleus, MOTS-c is encoded in the DNA of mitochondria, the “powerhouses” of cells that convert food to energy. MOTS-c was first thought to play a role only in counteracting diet-induced and age-dependent insulin resistance – effects commonly associated with exercising.

“It’s been thought for the longest time that the immune system is exclusively encoded in the nuclear genome,” said USC Associate Professor of Gerontology Changhan David Lee. “Now we’re bringing into play an immune regulator that’s encoded in the mitochondrial genome.”

According to Lee, the mitochondrial genome “encodes for previously unknown genes that yield small proteins with multiple physiological roles, including aging, exercise, metabolism, and immunity.” Further studies on the molecular mechanism of mitochondrial-encoded peptides such as MOTS-c may provide “novel therapeutic targets” for various autoimmune conditions.

Tags: , , ,

Category: Education, Features

Comments are closed.

Subscribe to HCA for exclusive updates

Top Viewed News

12 simple steps to a healthy lifestyle

12 simple steps to a healthy lifestyle

Now that the world has returned to normalcy following the pandemic, everyone is back to their daily routines and encounters with stress... Read More

AZBIL: Envisioning the Future of Hospitals

AZBIL: Envisioning the Future of Hospitals

As we strive to be the hospital of choice, why not refine our commitment to excellence beyond the pivotal mission of saving lives?... Read More

Study Unlocks Key Findings on Asian Carriers of Breast Cancer

Study Unlocks Key Findings on Asian Carriers of Breast Cancer

Malaysian researchers at Cancer Research Malaysia (CRMY) and the University of Nottingham Malaysia (UNM) have published... Read More

 Unmasking the Risks of Mercury-Laden Cosmetics

Unmasking the Risks of Mercury-Laden Cosmetics

As the saying goes, beauty is in the eye of the beholder and thus subjective; but in some countries, the ideal of beauty begins... Read More

5 key hospital etiquettes to be mindful of when visiting a sick patient

5 key hospital etiquettes to be mindful of when visiting a sick patient

In moments of illness, the presence of loved ones can comfort and support. However, it’s important for visitors... Read More

Free counters!

2025 Exhibitions



2025 Events


8-11 May
Vietnam Medi-Pharm
MITEC, KL
www.vietnammedipharm.vn


21-22 May
HealthTechX Asia
Sands Expo & Convention Centre, Singapore
www.healthtechx-asia.com


5-7 June
Medical Taiwan
Taipei Nangang Exhibition Center, Taipei, Taiwan
www.medicaltaiwan.com.tw


9-11 June
APHM International Healthcare Conference & Exhibition
KL Convention Centere, Kuala Lumpur, Malaysia
www.aphmconferences.com


12-14 June
International Health Industry Expo
China
www.ihe-china.com


24-26 June
CPhI China
SNIEC, Shanghai, China
www.cphi.com


25-26 June
Health Facilities Asia
Singapore
www.www.iqpc.com


25-27 June
Japan Health
INTEX Osaka, Japan
www.japanhealthonline.com


26-27 June
OSH India South
Chennai Trade Center, Bangalore
www.oshindia.com


9-11 July
Medical Device Development (MEDIX) – Osaka
Makuhari Messe, Japan
www.manufacturing-world.jp


14-16 July
Lab Asia
Kuala Lumpur Convention Centre (KLCC), Malaysia
www.lab-asia.com


16-18 July
Medlab Asia | Asia Health
Malaysia International Trade & Exhibition Centre, Kuala Lumpur
www.medlabasia.com


13-15 August
Philippines Medical
SMX Convention Center Manila Philippines
www.philmedical.com


21-23 August
REHACARE China
Suzhou, China
www.rehacare-c.com


21-23 August
Medical Fair China
Suzhou, China
www.medicalfair.cn


3-5 September
Bio Asia Pacific
BITEC, Bangkok
www.bioasiapacific.com


9-12 September
China Dental Show
National Exhibition and Convention Center (Shanghai)
www.chinadentalshow.com


10-11 September
Hospital Management Asia
Shangri-La Kuala Lumpur, Malaysia
www.hospitalmanagementasia.com


10-12 September
Medical Fair Thailand
BITEC, Bangkok
www.medicalfair-thailand.com


10-12 September
Malaysia Pharma and Healthcare Expo
Kuala Lumpur, Malaysia
www.mphcexpo.com


11-13 September
Bio Asia Pacific
BITEC, Bangkok
www.bioasiapacific.com


24-26 September
Medtec China
Shanghai, China
www.en.medtecchina.com


9-11 October
Medical Japan Tokyo
Makuhari Messe, Japan
www.medical-jpn.jp


17-19 October
Health Asia
BITEC, Bangkok
www.health-asia.com


17-19 October
Health Asia
BITEC, Bangkok
www.health-asia.com


7-8 November
Eldercare Exhibition and Conference Asia (ELDEX Asia)
Suntex Singapore Exhibition and Convention Centre
www.eldexasia.com


10-12 November
Saudi International Pharma Expo
Riyadh International Convention and Exhibition Center
www.saudipharmaexpo.com


10-12 November
Saudi International MedLab Expo
Riyadh International Convention and Exhibition Center
www.saudimedlabexpo.com


27-29 November
International Wellness Expo (IWE 2025)
METIC, Malaysia
www.internationalwellnessexpo.com


2026 Events


9-12 Febuary
Arab Health
Dubai World Trade Centre
www.arabhealthonline.com


15-17 April
Lab Indonesia
Jakarta Convention Center, Jakarta, Indonesia
www.lab-indo.com


9-11 September
Medical Fair Asia
Marina Bay Sands, Singapore
www.medicalfair-asia.com


9-11 September
Medical Manufacturing Asia
Marina Bay Sands, Singapore
www.medmanufacturing-asia.com